<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359956</url>
  </required_header>
  <id_info>
    <org_study_id>SICOG 0109</org_study_id>
    <nct_id>NCT01359956</nct_id>
  </id_info>
  <brief_title>Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma</brief_title>
  <acronym>SICOG 0109</acronym>
  <official_title>Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated two chemotherapy regimens with and without the addition of interferon in
      patients with advanced or recurrent melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>18 weeks from start of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related toxicity</measure>
    <time_frame>at end of each 3 week cycle of therapy</time_frame>
    <description>worst grade CTC toxicity, for each cycle and overall, will be reported for each treatment arm</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination chemotherapy without interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination chemotherapy with interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single agent dacarbazine without interferon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single agent dacarbazine plus interferon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>900 mg / m2 every 3 weeks</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fotemustine</intervention_name>
    <description>100 mg / m2 every 3 weeks</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa-2b</intervention_name>
    <description>5 M units every 3 weeks</description>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of malignant melanoma in advanced stage or
             recurrent after surgery, and not amenable to further surgery or local therapy.

          -  Presence of measurable disease

          -  Age &gt; or = 18 years and &lt; or = 75 years

          -  Performance status (ECOG) 0 - 2 (Appendix 2)

          -  Life expectancy ³ 3 months

          -  Adequate bone marrow function (ANC ³ 2,000/mmc; PTL ³ 100,000/mmc; Hb ³ 10 gr/dl),
             normal liver and renal function (bilirubin &lt; 1.25 x N, creatinine &lt; 1.25 x N, SGOT,
             SGPT &lt; 3 times upper normal limit of testing laboratory.

          -  Written, informed consent prior to study specific procedures, with the understanding
             that the patient has the right to withdraw from the study at any time, without
             prejudice.

          -  Prior surgery &gt; 3 weeks from initiating .

          -  If palliative radiation is needed, in case of non target lesions, it must be given
             prior to initiating chemotherapy. If palliative radiation is required during the study
             the patient should be permanently discontinued from further treatment.

          -  Adequate contraceptive measures during study participation for sexually active
             patients of child bearing potential must implement.

        Exclusion Criteria:

          -  Previous or concurrent malignancies at other sites with the exception of surgically
             cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the
             skin.

          -  Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed)

          -  Known HIV disease.

          -  Concurrent treatment with other experimental drugs.

          -  Concurrent chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and
             replacement steroids), radiation therapy

          -  Pregnant or lactating females Previous or concurrent malignancies at other sites with
             the exception of surgically cured carcinoma in-site of the cervix and basal or
             squamous cell carcinoma of the skin.

        Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed) Known HIV disease.
        Concurrent treatment with other experimental drugs. Concurrent chemotherapy, immunotherapy,
        hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo A Ascierto, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Daponte, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simona Signoriello, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <results_reference>
    <citation>Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38.</citation>
    <PMID>23402397</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fotemustine</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

